Fyzoclad: Withdrawal of the marketing authorisation application
adalimumab
Table of contents
Overview
On 5 December 2018, Pfizer Europe MA EEIG officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Fyzoclad, for the treatment of a number of inflammatory diseases.
Key facts
Name |
Fyzoclad |
Product number |
EMEA/H/C/005253 |
International non-proprietary name (INN) or common name |
|
Active substance |
|
Date of withdrawal |
05/12/2018 |
Company making the application | |
Withdrawal type |
Initial authorisation |
Related information on withdrawals
A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.
An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').